BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27832143)

  • 1. Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.
    Loftfield E; O'Brien TR; Pfeiffer RM; Howell CD; Horst R; Prokunina-Olsson L; Weinstein SJ; Albanes D; Morgan TR; Freedman ND
    PLoS One; 2016; 11(11):e0166036. PubMed ID: 27832143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
    Yokoyama S; Takahashi S; Kawakami Y; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
    J Viral Hepat; 2014 May; 21(5):348-56. PubMed ID: 24716637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
    World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials.
    Kim HB; Myung SK; Lee YJ; Park BJ;
    J Hum Nutr Diet; 2018 Apr; 31(2):168-177. PubMed ID: 28833855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
    AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.
    Bitetto D; Fabris C; Fornasiere E; Pipan C; Fumolo E; Cussigh A; Bignulin S; Cmet S; Fontanini E; Falleti E; Martinella R; Pirisi M; Toniutto P
    Transpl Int; 2011 Jan; 24(1):43-50. PubMed ID: 20649944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
    Esmat G; El Raziky M; Elsharkawy A; Sabry D; Hassany M; Ahmed A; Assem N; El Kassas M; Doss W
    J Interferon Cytokine Res; 2015 Jan; 35(1):49-54. PubMed ID: 25061714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
    Mohamed AA; Sabry NA; Abbassi MM; Ibrahim WA; Ali-Eldin ZA
    Acta Gastroenterol Belg; 2013 Mar; 76(1):38-44. PubMed ID: 23650781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution.
    Larrubia JR; Lokhande MU; Moreno-Cubero E; García-Garzón S; Miquel J; Parra-Cid T; González-Praetorious A; Perna C; Lázaro A; Sanz-de-Villalobos E
    Cell Immunol; 2013; 286(1-2):31-8. PubMed ID: 24287274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Int J Infect Dis; 2011 Nov; 15(11):e740-6. PubMed ID: 21803628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C.
    Yang SS; Fu LS; Chang CS; Yeh HZ; Chen GH; Kao JH
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1789-93. PubMed ID: 17074015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.
    Hui CK; Yuen MF; Sablon E; Chan AO; Wong BC; Lai CL
    J Infect Dis; 2003 Apr; 187(7):1071-4. PubMed ID: 12660921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus.
    Rocco A; Compare D; Coccoli P; Esposito C; Di Spirito A; Barbato A; Strazzullo P; Nardone G
    Gut; 2013 May; 62(5):766-73. PubMed ID: 22810757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.